# SkinBioTherapeutics plc SkinBiotix® technology successful in stability testing

- Link: https://www.directorstalkinterviews.com/skinbiotherapeutics-plc-skinbiotix-technology-successful-in-stability-testing/412757608
- Published: 2018-09-03T07:22:14+01:00
- Author: Giles Arbor

**SkinBioTherapeutics plc** (LON:SBTX), a life science company focused on skin health,
has today provided an update to its announcement of 16 August 2018. The stability
criteria required for its [human study](https://www.directorstalkinterviews.com/company/open-orphan-plc/orph.l)
has been met and the Company expects to commence the study in September as planned.

>  **Dr Cath O’Neill, CEO of SkinBioTherapeutics, commented:** “Demonstrating the
> extended stability of the cream formulation was a key step to commencing the human
> study. This remains on track to start this month.”

SkinBioTherapeutics is a life science company focused on skin health. The Company’s
proprietary platform technology, SkinBiotix®, is based upon discoveries made by 
CEO Dr. Catherine O’Neill and Professor Andrew McBain.

The company platform applies research discoveries made on the activities of lysates
derived from probiotic bacteria when applied to the skin. It has shown that the 
SkinBiotix® platform can improve the barrier effect of skin models, protect skin
models from infection and repair skin models. Proof of principle studies have shown
that the SkinBiotix® platform has beneficial attributes applicable to each of these
areas.

SkinBioTherapeutics plc received seed funding from the Tech Transfer office of the
University of Manchester for the discovery of SkinBiotix®. The platform was subsequently
spun out of the University of Manchester in March 2016 and was funded by OptiBiotix
Health Plc (LON:OPTI).

The Company joined AIM in April 2017 concurrent with raising £4.5 million from a
placing of new ordinary shares.

Share on: